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Treatment with simvastatin suppresses the development of experimental
abdominal aortic aneurysm in normal and hypercholesterolemic mice
Steinmetz EF, Buckley C, Shames ML, et al. Ann Surg 2005;241:92-101.
Conclusions: Simvastatin suppresses the development of experimental
abdominal aortic aneurysm (AAA) independent of its lipid-lowering effects
in normal and hypercholesterolemic mice.
Summary: Statins appear to have a number of favorable effects on
decreasing progression and limiting development of vascular disease inde-
pendent of their cholesterol lowering effects. In this study, using a mouse
model, the authors sought to determine whether statins have an influence on
the development of AAAs. C57B1-6 wild-type and hypercholesterolemic,
apolipoprotein E (apoE)-deficient mice underwent transient perfusion of
the aorta with elastase to induce an AAA. This was followed by either
subcutaneous treatment with simvastatin at 2 mg/kg per day or treatment
with vehicle only. Aortic diameter was measured before elastase perfusion
and 14 days after elastase perfusion. An AAA was defined as a change in
aortic diameter of 100%.
After elastase profusion of the aorta, simvastatin-treated wild-type mice
had a 21% reduction in elastase-induced increased aortic diameter and a 33%
reduction in AAA compared with mice treated with vehicle only. In the
apoE-deficient, hypercholesterolemic mice, simvastatin was associated with
a 26% reduction in elastase-induced changes in aortic diameter and a 37%
reduction in AAA. Simvastatin had no effect on serum cholesterol levels in
either the hypercholesterolemic or wild-type mice. Preservation of elastin
in the aortic media, as well as vascular smooth muscle cells and a relative
reduction in aortic wall expression of matrix metalloproteinase
(MMP)-9, and a relative increase in expression of tissue inhibitor of
metalloproteinase-1 were associated with suppression of AAA in simva-
statin treated mice.
Comment: These authors have previously documented suppression of
elastin-induced aneurysm formation using the MMP inhibitor doxycycline.
The current results may ultimately translate into a clinical recommendation
for statin treatment of patients with small AAA to lower rates of aneurysm
diameter increase.
Intensive lipid lowering with atorvastatin in patients with stable coro-
nary disease
LaRosa JC, Grundy SM, Waters DD, et al, and the Treating to New Targets
(TNT) Investigators. N Engl J Med 2005;352:1425-35.
Conclusion: In patients with stable coronary heart disease, intensive
lipid-lowering therapy with 80 mg of atorvastatin daily provides additional
clinical benefit beyond that with treatment of 10 mg of atorvastatin daily.
Summary: Recent trials indicate intensive lipid-lowering therapy be-
yond traditionally recommended levels in patients with acute coronary
syndromes provides increased benefit with respect to cardiovascular end-
points compared with traditional lipid-lowering therapy in such patients
(N Engl J Med 2004;50:1495-504, and J Am Col Cardiology 2004;44:
1772-9). This study investigated the safety and efficacy of lowering low-
density-lipoprotein (LDL) cholesterol 100 mg/dL in patients with stable
coronary disease. Eligible patients were men and women 35 to 75 years of
age who had clinically evident coronary heart disease. Screening of 18,469
patients took place at 256 sites in 14 countries, with 83.7% of these patients
deemed eligible to enter the open-label run-in period of the study. Of these,
5,461 patients were excluded after the open label run in phase. Most
exclusions were secondary to failure to meet randomization criteria. There
were 10,001 patients ultimately randomized to receive double-blind treat-
ment with either 10 mg or 80 mg daily of atorvastatin. The primary end
point was the occurrence of a first major cardiovascular event, defined as
death from coronary heart disease, nonfatal nonprocedure-related myocar-
dial infarction, fatal or nonfatal stroke, or resuscitation after cardiac arrest.
Randomization took place between July 1998 and December 1999.
During treatment, the mean LDL cholesterol levels were 77 mg/dL
with 80 mg of atorvastatin daily and 101 mg/dL with 10 mg of atorvastatin
daily. Persistent elevations in liver aminotransferase occurred in 1.2% of the
80 mg of atorvastatin daily group versus 0.2% in the 10 mg of atorvastatin
daily group (P  .001). A primary end point occurred in 434 (8.7%) of the
patients receiving 80 mg of atorvastatin and in 548 (10.9%) of the patients
receiving 10 mg of atorvastatin.
The absolute reduction in the rate of major cardiovascular events was
2.2%, with a 22% relative reduction (hazard ratio, 0.78; 95% confidence
interval, 0.69 to 0.89; P  .001). Overall, mortality did not differ between
the two groups. Discontinuation of treatment because of adverse events
occurred in 7.2% of the 80mg of atorvastatin group versus 5.3% in the 10mg
of atorvastatin group (P 0.001). Five cases rhabdomyolysis occurred, 2 in
the 80 mg of atorvastatin group and 3 in the 10 mg of atorvastatin group.
Comment:The safety data for the two doses of atorvastatin used in this
trial are consistent with other large-scale trials of this drug (N Engl J Med
2004;350:1495-504 and Lancet 2003;361:1149-58). The trial was not
adequately powered to detect differences in risk of death from any cause.
Nevertheless, the study is part of a growing body of evidence suggesting that
lowering LDL cholesterol levels significantly below traditionally recom-
mended values has clinical benefit.
Complications of the COX-II inhibitors parecoxib and valdecoxib after
cardiac surgery
Nussmeier NA, Whelton AA, Brown MT, et al. N Engl J Med 2005;352:
1081-91.
Conclusion: Patients treated with coronary artery bypass grafting
(CABG) who used parecoxib and valdecoxib for postoperative pain control
had an increased incidence of postoperative cardiovascular events.
Summary: There is serious concern that the use of cyclooxygenase-II
(COX-II) inhibitors in nonsurgical settings increases the risk of thrombo-
embolic events long-term. The authors sought to evaluate the safety of
parecoxib and valdecoxib after coronary artery bypass grafting. This was a
randomized double-blind study. After coronary artery bypass grafting, pa-
tients were treated for 10 days and followed for 30 days. The COX-II
inhibitors used in this study were valdecoxib (Bextra, Pfizer, New York, NY)
and its intravenous prodrug parecoxib (Dymastat, Pfizer). After coronary
artery bypass grafting, patients were randomly assigned to receive intrave-
nous parecoxib for at least 3 days followed by oral valdecoxib through day
10, or were assigned to be treated with intravenous placebo followed by oral
valdecoxib, or placebo, for 10 days. All patients also had access to opiate-
based medications. The study enrolled 1,671 patients. The primary end
point was the frequency of predefined adverse events, including cardiovas-
cular events, renal failure or dysfunction, gastroduodenal ulceration, and
wound-healing complications.
Compared with the group given placebo alone, the groups given
parecoxib and valdecoxib, and placebo and valdecoxib, all had higher rates of
confirmed adverse events (4.0% in the placebo group vs 7.4% in each of the
coxib groups; risk ratio for each comparison, 1.9; 95% confidence interval
[CI], 1.1 to 3.2; P  .02). Cardiovascular events, including myocardial
infarction, cardiac arrest, stroke, and pulmonary embolism, were particularly
more frequent among patients given parecoxib and valdecoxib (2.0% vs
0.5%; risk ratio 3.7; 95% CI, 1.0 to 13.5; P  .03).
Comment: Previous data on the adverse effects of COX-II inhibitors
have focused on long-term thromboembolic risk. There have been data to
suggest that COX-II inhibitors could exert significant opiate-sparing effects
after surgical procedures. The current study, however, suggests patients with
coronary artery disease who undergo CABG may be adversely impacted by
the use of COX-II inhibitors to control perioperative pain. Although no
such data currently exists to implicate COX-II inhibitors and increased
cardiovascular complications after peripheral vascular surgery, the current
data may imply that COX-II inhibitors should be avoided in patients
undergoing peripheral vascular surgery as well.
Cilostazol prevents the progression of symptomatic intracranial arterial
stenosis: The multicenter double-blind placebo-controlled trial of
cilostazol in symptomatic intracranial arterial stenosis
Kwon SU, Cho YJ, Koo JS, et al. Stroke 2005;36:782-6.
Conclusion: Cilostazol appears to prevent the progression of intercra-
nial arterial stenoses that have previously been associated with symptoms.
Summary: Cilostazol appears to have a number of pleiotropic effects
other than improvement of intermittent claudication. It has been shown to
decrease restenosis after coronary angioplasty and stenting and reduce the
growth rate of carotid intimal medial thickness in patients with diabetes
mellitus.
In this trial, the authors investigated the ability of cilostazol to prevent the
progression of intercranial arterial stenoses associated with symptoms. The
patients enrolled were 35 to 80 years of age and had a recent ischemic stroke
within 2 weeks that was believed to be associated with stenosis in the M1
segment of the middle cerebral artery or stenosis of the basilar artery. Patients
were required to have magnetic resonance angiographic (MRA) evidence of
stenosis in the noted arteries as well as acute ischemic changes on magnetic
resonance imaging. Participants were followed-up at 1, 3, 5, and 6 months.
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